Consensus Amgen Inc.

Stocks

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX 02:21:17 16/10/26 am AEDT			5-day change	1st Jan Change
439.48 ^USD	+3.14%		+7.77%	+34.15%

09:46pm	Goldman Sachs Adjusts Price Target on Amgen to $481 From $475	MT
13/10	Goldman Sachs Adjusts Price Target on Amgen to $475 From $450	MT

Evolution of the Average Target: Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

0e6af34167f572b28bf0b1.ladNumWNE6mauuGliWmHPC517loe2N0JoFZtHSJhsQc.7PYbg1W-IITp09XN5FzhbVQ-g25Ns-1b-W4rc1FX01jUyTzVV-Jf-_zzhg~6b3bb2f7d3a78aaa7df9e84f8aeaf002

Analysts' recommendations: Amgen Inc.

09:46pm	Goldman Sachs Adjusts Price Target on Amgen to $481 From $475	MT
13/10	Goldman Sachs Adjusts Price Target on Amgen to $475 From $450	MT
13/10	Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says	MT
12/10	BofA Securities Adjusts Amgen Price Target to $328 From $317, Maintains Underperform Rating	MT
12/10	Wells Fargo Adjusts Price Target on Amgen to $430 From $435	MT
12/10	BMO Capital Adjusts Price Target on Amgen to $415 From $450	MT
10/10	UBS Adjusts Price Target on Amgen to $470 From $430, Maintains Buy Rating	MT
08/10	RBC Raises Price Target on Amgen to $430 From $400, Keeps Outperform Rating	MT
07/10	Morgan Stanley Adjusts Price Target on Amgen to $359 From $362	MT
29/09	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT
23/09	Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating	MT
10/09	HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445	MT
09/09	Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says	MT
08/09	Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating	MT
08/09	BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450	MT
08/09	Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy…
07/09	Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks…
04/09	Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating	MT
20/08	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
19/08	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
19/08	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
18/08	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
18/08	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
18/08	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
13/08	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AMGEN INC.					-7.35%
	ELI LILLY AND COMPANY					+9.87%
	JOHNSON & JOHNSON					+9.83%
	ABBVIE INC.					-0.31%
	MERCK & CO., INC.					+7.65%
	ROCHE HOLDING AG					+1.71%
	NOVARTIS AG					+2.68%
	ASTRAZENECA PLC					+29.22%
	GILEAD SCIENCES, INC.					+3.93%
	NOVO NORDISK A/S					+19.76%
	Average					+7.70%
	Weighted average by Cap.					+7.54%